Viridian Therapeutics, Inc – Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED) – – VRDN-002 achieved a substantially extended half-life of 30-40 days in healthy volunteers with a sustained IGF-1 response and a favorable safety and tolerability profile – – Ended […]